[Evaluation of the effect of ilaprazole on intragastric pH in patients with duodenal ulcer].
OBJECTIVE
To evaluate the effect of ilaprazole enteric tablets on intragastric pH in duodenal ulcer patients.


METHODS
A randomized, double blind, positive controlled clinical trial was carried out. A total of forty-two patients with duodenal ulcer were randomized into low dose ilaprazole group (5 mg/d), medium dose ilaprazole group (10 mg/d), high dose ilaprazole group (20 mg/d) and omeprazole group (20 mg/d). An ambulatory 24 hour intragastric pH study was performed at the fifth treatment day. Fraction time pH above 3, 4 or 5, median values of 24 hour diurnal pH and 12 hour nocturnal pH, the percentage of patients with total time pH above 3, 4 or 5 at least for 18 hours were evaluated.


RESULTS
There were no significant differences of fraction time pH above 3 or 4, median values of 24 hour diurnal pH and 12 hour nocturnal pH and the percentage of patients with total time pH above 3, 4 or 5 at least for 18 hours among all the groups with different doses of ilaprazole and the omeprazole group. The fraction time pH above 5 in medium and high dose ilaprazole groups were (87.96 + or - 12.29)% and (89.86 + or - 15.18)% respectively, which was higher than that in low dose ilaprazole group [(67.17 + or - 30.16)%] and omeprazole group [(76.14 + or - 16.75)%], P < 0.05.


CONCLUSIONS
Ilaprazole has a strong effect on intragastric acid control with a dose dependent trend.
Zhou
Li-ya
LY
Department of Gastroenterology, the Third Hospital, Peking University, Beijing 100191, China. liyazhou@medmail.com.cn
Lin
San-ren
SR
Yang
Yun-sheng
YS
Zhang
Shu-tian
ST
Yuan
Yao-zong
YZ
Shi
Rui-hua
RH
Hou
Xiao-hua
XH
Xia
Jie-lai
JL
Hu
Hai-tang
HT
Qin
Xiang-hong
XH
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000328:Adult; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D001562:Benzimidazoles / Q000627:therapeutic use*; D004311:Double-Blind Method; D004381:Duodenal Ulcer / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000627:therapeutic use; D054328:Proton Pump Inhibitors / Q000627:therapeutic use*; D013270:Stomach / Q000503:physiopathology*; D013454:Sulfoxides / Q000627:therapeutic use*; D055815:Young Adult
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D054328:Proton Pump Inhibitors; D013454:Sulfoxides; C119615:ilaprazole; D009853:Omeprazole